Phase I/II Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Stanford University
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Michaela Liedtke, Stanford University
ClinicalTrials.gov Identifier:
NCT01355705
First received: May 16, 2011
Last updated: September 20, 2013
Last verified: September 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2016
  Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)